César Homero Gutiérrez-Aguirre

8PUBLICATIONS
23CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cardiovascular medicine and haematology not elsewhere classifiedRegenerative medicine (incl. stem cells)AutoimmunityAnaesthesiology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Nov 24, 2024
Romiplostim, low-dose rituximab and high-dose dexamethasone for newly diagnosed immune thrombocytopenia: A pilot study.

Perla R Colunga-Pedraza, Fernando De la Garza-Salazar, Héctor A Vaquera-Alfaro

|Jan 16, 2024
Graft-versus-host disease after an outpatient peripheral blood hematopoietic cell transplant using reduced-intensity conditioning: a single-center LATAM experience.

José Carlos Jaime-Pérez, Jesús Daniel Meléndez-Flores, Jorge Valdespino-Valdes

|Apr 12, 2022
High dose melphalan is an adequate preparative regimen for autologous hematopoietic stem cell transplantation in relapsed/refractory lymphoma.

José A Fernández-Gutiérrez, Oscar A Reyes-Cisneros, Mark R Litzow

|Sep 29, 2021
Autologous ATG-free hematopoietic stem cell transplantation for refractory autoimmune rheumatic diseases: a Latin American cohort.

José Carlos Jaime-Pérez, Mariana González-Treviño, Jesús D Meléndez-Flores

|Jan 25, 2021
Results of a completely outpatient autologous stem cell transplant program for lymphoma patients receiving reduced-intensity conditioning.

José C Jaime-Pérez, Marcela Hernández-Coronado, Ernesto Picón-Galindo

|Oct 17, 2019
Reduced-dose plerixafor as a mobilization strategy in autologous hematopoietic cell transplantation: a proof of concept study.

Cesar Homero Gutiérrez-Aguirre, Dalila Marisol Alvarado-Navarro, Alain Palomares-Leal

Pageof 2